Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects

    Research output: Contribution to journalReview article

    8 Scopus citations

    Abstract

    Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

    Original languageEnglish (US)
    Pages (from-to)255-271
    Number of pages17
    JournalMini-Reviews in Medicinal Chemistry
    Volume4
    Issue number3
    DOIs
    StatePublished - Mar 1 2004

    Keywords

    • AML
    • FLT3
    • KIT
    • Kinase inhibitor
    • PDGFR
    • Tyrosine kinase

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology
    • Drug Discovery
    • Cancer Research

    Fingerprint Dive into the research topics of 'Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects'. Together they form a unique fingerprint.

  • Cite this